FibroGen, Inc. (NASDAQ: FGEN) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) of FG-3165, a galectin-9 (Gal9) targeted monoclonal antibody under development for treatment of solid tumors characterized by high Gal9 levels of expression.
6/3/2024
Cibus, Inc. (Nasdaq: CBUS) (“Cibus” or the “Company), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced it has successfully made the next generation edits in Canola associated with a new third mode of action for White Mold (Sclerotinia) resistance. These new edited plants will now undergo disease resistance testing in a controlled environment. If successful, Cibus expects this third mode of action trait, along with Cibus’ other two modes of action traits, to provide durable resistance for White Mold in Canola. Today’s announcement represents a major development in the Company’s progress toward providing durable White Mold resistance.
5/30/2024
Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired an interest in Agios Pharmaceuticals’ royalty on Servier’s vorasidenib for $905 million in upfront cash contingent on U.S. Food and Drug Administration (FDA) approval of vorasidenib.
5/28/2024
Cibus, Inc. (Nasdaq: CBUS) (the "Company"), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, applauds the Canadian Food Inspection Agency (CFIA), Animal Feed Division’s publication of its updated feed guidelines clarifying requirements for new plant varieties developed using applications of gene editing. The guidelines confirm that CFIA intends to follow a product, rather than process-based, approach to regulation and adds Canada to a growing list of countries that have endorsed policies that will regulate Cibus' Rapid Trait Development System™ (RTDS®) gene editing technologies similar to conventional breeding.
5/15/2024
ADC Therapeutics SA (NYSE: ADCT) today announced that initial data from an investigator-initiated Phase 2 clinical trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) demonstrated a high response rate in patients with relapsed/refractory (r/r) marginal zone lymphoma (MZL).
5/6/2024
VERIGRAFT was selected as an EIC ambassador and co-organiser and will be one of only 15 companies that the European Innovation Council (EIC) will show off to the world at the European Pavilion at the BIO International Convention 2024 in San Diego June 3-6.
4/26/2024
Growmark has partnered with Intelinair, an ag data analytics company, on a new digital agronomy application to equip its farmer customers with data-driven insights to improve agronomic outcomes throughout the growing season.
4/22/2024
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced positive topline results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD). Topline results from our second Phase 3 study, Study 502, are anticipated late in the second quarter of this year.
4/16/2024
ADC Therapeutics SA (NYSE: ADCT) today announced the completion of dose escalation in LOTIS-7, a Phase 1b open-label clinical trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with bispecific antibodies glofitamab or mosunetuzumab in heavily pre-treated patients with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL).
4/4/2024
Cibus, Inc. (Nasdaq: CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that it has been named to Fast Company’s prestigious list of the World’s Most Innovative Companies of 2024, ranking as the 2nd most innovative company in the agriculture category.
3/19/2024
Unprecedented collaboration will build the most powerful, fully integrated, AI-driven drug discovery and development platform to dramatically improve pharmaceutical research and development (R&D) productivity and bring novel therapeutics to patients faster and more cost-effectively than traditional approaches.
2/29/2024
Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses Non-GMO plant traits to seed companies, today announced that it has entered into a US Development Agreement with Loveland Products Inc., a subsidiary of Nutrien Ltd. (TSX and NYSE: NTR). Cibus has agreed to collaborate with Loveland Products to provide traits into Loveland’s elite rice seed genetics.
2/26/2024
Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies, welcomes the vote of the European Parliament on 7th February in favour of new legislation for New Genomic Techniques (NGTs). Cibus applauds the EU Parliament supporting a science-based approach developed following many years of discussion and engagement with stakeholders and expert groups.
2/7/2024
VERIGRAFT starts 2024 off with a major progress in our TECVI-1 first-in-man trial: Half of the patients have been treated.
1/11/2024
Cibus, Inc. (NASDAQ: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced that the Company has successfully regenerated plants from single cells in a wheat cultivar. This is a major breakthrough for Cibus as well as for the industry.
1/9/2024
Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses gene edited plant traits to seed companies for royalties, today announced that it has entered into a Collaboration Agreement with Interoc, a company with more than 25 years in Latin America, focused on the research and development of solutions for agriculture. Starting with Cibus’ rice herbicide tolerance traits, Cibus has agreed to partner with Interoc to provide traits for Interoc’s elite rice seed genetics.
1/4/2024
ADC Therapeutics SA (NYSE: ADCT) today provided business updates. “During 2023, we took a number of decisive actions to help position the Company for success in 2024 and beyond. We prioritized our pipeline, strengthened our organization and implemented a disciplined capital allocation model to generate cost efficiencies,” said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. “We believe we are starting to see signs of the commercial turnaround. We are also encouraged to see positive initial signals in the LOTIS-7 trial of ZYNLONTA in combination with bispecifics as well as early signs of antitumor activity in the Phase 1b trial of ADCT-601. We now expect our cash runway to extend into the fourth quarter of 2025 and believe we are on a path to unlock the substantial value in the Company.”
1/4/2024
ADC Therapeutics SA (NYSE: ADCT) today announced initial results from an investigator-initiated Phase 2 clinical trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab demonstrated a high response rate in patients with relapsed or refractory (r/r) follicular lymphoma (FL). The data from the single-institution study conducted at the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine were reported during an oral presentation yesterday at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition by the study’s lead investigator, Juan Pablo Alderuccio, MD, associate professor of medicine and hematologist at Sylvester.
12/12/2023
Cibus, Inc. (NASDAQ: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies, acknowledges the European Union notification to World Trade Organization (WTO) members on the European Commission proposal for regulation of plants obtained from New Genomic Techniques (NGTs) on 31st October. The notification is intended to ensure any potential trade barriers are avoided and invites comments from WTO members by the year end.
12/1/2023
Royalty Pharma plc (Nasdaq: RPRX) and Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today a collaboration to further accelerate the clinical research program for Teva’s olanzapine LAI (TEV-‘749) by entering into a funding agreement of up to $125 million to offset program costs. Olanzapine LAI (TEV-‘749) is a once-monthly subcutaneous long-acting injection of the atypical antipsychotic olanzapine that is currently in Phase 3 for the treatment of schizophrenia and has the potential to be the first long-acting olanzapine with a favorable safety profile.
11/14/2023
